Pharmaceutical Industry – Market Development (Essential Notes)

Definition & Legal BasisGerman Medicinal Products Act (AMG) §2: substances/preparations intended for human/animal use to heal, alleviate, prevent or influence physiology/diagnosis.Key criteria: intended use + pharmacological/immunological/metabolic action.Historical Trigger1957{-}1961$Contergan (thalidomide): up to$10{,}000 severely disabled births ➔ mandatory controlled clinical trials & creation of Federal Ministry of Health.Core Policy Tensions (“Spannungsfeld”)Public health: efficacy, safety, quality ➔ Federal Ministry of Health / DG Santé.Economy & innovation: tradable products ➔ Min. of Economic Affairs / DG Enterprise.Social protection: reimbursement, cost containment ➔ SHI funds ▸ cost-benefit.Regulatory LayersSpheres: \text{Wirtschaftsrecht}$,$\text{Sozialrecht}$,$\text{Gesundheitsrecht}$.Levels: EU (marketing authorisation, patents), National (pricing, reimbursement, dispensing rules).Simple Expenditure Model$\text{Consumption (DDD)} \times \text{Price} = \text{Spending}$.Detailed:$\text{Manufacturer price}+\text{wholesale/ pharmacy mark-up}+\text{VAT}$$\rightarrow$official price$\rightarrow$minus rebates$\rightarrow public payer outlay.Global PatternsHigher GDP ⇒ higher DDD per capita (except China & USA deviations).2023 global spend ≈ 1.6\ \text{trillion US\$}$(≈$200\ \text{US\$}/\text{capita}$≈$0.5\ \text{US\$}/\text{DDD}$).Regional spend per capita (2023): North America$>$Western Europe$>$Japan … Africa/ME lowest.International Price Comparisons2005-2011 studies: German list prices consistently among highest in Europe.2017 BIP-weighted top$250$patented drugs: Germany index$100$, others$65{-}82$.German Market SnapshotDistribution classes: OTC (freiverkäuflich), apothekenpflichtig, prescription-only; SHI reimbursement only for Rx.2023: ~$\text{90\%}$community pharmacies,$\text{10\%}$hospital sector.Portfolio (01/23): hundreds of manufacturers; each pack size/strength has unique PZN.SHI (GKV) Expenditure2023 share of total GKV spending: Hospitals$\approx32.6\%$, Medicines$\approx17.4\%$, Physicians$\approx16.3\%.2019-2023 trend: all three categories rising; drugs remain second-largest.Industrial SignificanceEU/US/Japan dominate production; Germany 2022 EU rank 4 (after CH, IT, BE).High R&D intensity: pharma 8.1\%$of sales (second only to electronics); highest productivity$\approx€261{,}000 GVA per employee.EU Framework Evolution1965 Directive 65/65/EEC: first harmonised rules.1975 Mutual Recognition; 1983 Multi-State.1989 Price Transparency Directive 89/105/EEC (only EU price rule).1995 EMA founded; centralised/decentralised procedures binding.2000 reform to streamline; ongoing move to data useful for reimbursement.2019 EMA headquarters → Amsterdam (post-Brexit).Definition & Legal BasisGerman Medicinal Products Act (AMG) §2: substances/preparations intended for human/animal use to heal, alleviate, prevent or influence physiology/diagnosis.Key criteria: intended use + pharmacological/immunological/metabolic action.Historical Trigger1957{-}1961$Contergan (thalidomide): up to$10{,}000 severely disabled births ➔ mandatory controlled clinical trials & creation of Federal Ministry of Health.Core Policy Tensions (“Spannungsfeld”)Public health: efficacy, safety, quality ➔ Federal Ministry of Health / DG Santé.Economy & innovation: tradable products ➔ Min. of Economic Affairs / DG Enterprise.Social protection: reimbursement, cost containment ➔ SHI funds ▸ cost-benefit.Regulatory LayersSpheres: ext{Wirtschaftsrecht}$,$ ext{Sozialrecht}$,$ ext{Gesundheitsrecht}$.Levels: EU (marketing authorisation, patents), National (pricing, reimbursement, dispensing rules).Simple Expenditure Model$ ext{Consumption (DDD)} \times \text{Price} = \text{Spending}$.Detailed:$ ext{Manufacturer price}+\text{wholesale/ pharmacy mark-up}+\text{VAT}$$ightarrow$official price$ightarrow$minus rebates$ightarrow public payer outlay.Global PatternsHigher GDP ⇒ higher DDD per capita (except China & USA deviations).2023 global spend ≈ 1.6\ \text{trillion US\$}$(≈$200\ \text{US\$}/\text{capita}$≈$0.5\ \text{US\$}/\text{DDD}$).Regional spend per capita (2023): North America$>$Western Europe$>$Japan … Africa/ME lowest.International Price Comparisons2005-2011 studies: German list prices consistently among highest in Europe.2017 BIP-weighted top$250$patented drugs: Germany index$100$, others$65{-}82$.German Market SnapshotDistribution classes: OTC (freiverkäuflich), apothekenpflichtig, prescription-only; SHI reimbursement only for Rx.2023: ~$\text{90\%}$community pharmacies,$\text{10\%}$hospital sector.Portfolio (01/23): hundreds of manufacturers; each pack size/strength has unique PZN.SHI (GKV) Expenditure2023 share of total GKV spending: Hospitals$\approx32.6\%$, Medicines$\approx17.4\%$, Physicians$\approx16.3\%.2019-2023 trend: all three categories rising; drugs remain second-largest.Industrial SignificanceEU/US/Japan dominate production; Germany 2022 EU rank 4 (after CH, IT, BE).High R&D intensity: pharma 8.1\%$of sales (second only to electronics); highest productivity$\approx€261{,}000 GVA per employee.EU Framework Evolution1965 Directive 65/65/EEC: first harmonised rules.1975 Mutual Recognition; 1983 Multi-State.1989 Price Transparency Directive 89/105/EEC (only EU price rule).1995 EMA founded; centralised/decentralised procedures binding.2000 reform to streamline; ongoing move to data useful for reimbursement.2019 EMA headquarters → Amsterdam (post-Brexit).Key Points & Crux of the LectureDrug Regulation is Multifaceted: It balances public health (efficacy, safety, quality), economic innovation, and social protection (reimbursement, affordability).Historical Impact: Major events like the Contergan tragedy profoundly shaped modern drug regulation, leading to stringent clinical trial requirements.Layered Governance: The pharmaceutical sector is governed by complex regulatory layers, involving national and EU frameworks (e.g., marketing authorization, pricing, reimbursement).Economic Significance: Pharmaceuticals represent a substantial global and national expenditure, influenced by consumption and price, with significant industrial impact and high R&D intensity.German Specifics: Germany's market is characterized by high drug prices compared to other European countries, a dominant pharmacy distribution, and medicines being the second-largest SHI expenditure.Crux of the Lecture: The lecture emphasizes the dynamic and often contentious interplay between ensuring public access to safe and effective medicines at sustainable costs, fostering pharmaceutical innovation, and navigating complex national and international regulatory landscapes. This constant tension drives policy and market dynamics in the pharmaceutical sector.